Take-Home ECG Device Aids Syncope Diagnosis in ASPIRED Trial

The ASPIRED trial has provided new insights into the diagnosis of syncope, or unexplained fainting, by employing an extended electrocardiogram (ECG) monitoring protocol using a take-home device. This approach significantly increased the likelihood of an eventual diagnosis for patients who presented to emergency departments (EDs) with syncope, although it did not alter the frequency of their fainting episodes. The findings, published in the Journal of the American Medical Association (JAMA), offer a more effective strategy for identifying the underlying causes of recurrent fainting.

Historically, diagnosing syncope has been challenging due to its transient nature. Patients often undergo initial evaluations in the ED, which may not capture the event or its cause. The ASPIRED trial aimed to address this diagnostic gap by extending the monitoring period beyond the typical hospital stay. Participants in the trial were equipped with a portable ECG device that allowed for continuous or intermittent recording of their heart rhythm over an extended period, enabling the capture of events that might occur outside of a clinical setting. This extended monitoring protocol proved more successful in establishing a diagnosis compared to standard diagnostic approaches.

The ASPIRED trial enrolled 1,024 participants across 12 emergency departments in the United States. These participants had experienced at least one episode of syncope within the preceding 12 months and were presenting to the ED. The study compared an extended ECG monitoring protocol, which involved using a take-home device for up to 14 days, with standard diagnostic evaluations. The primary outcome was the rate of syncope diagnosis within 30 days of the ED visit. The results demonstrated a statistically significant increase in diagnostic yield with the extended monitoring strategy.

Specifically, the ASPIRED trial reported that the extended ECG monitoring protocol led to a diagnosis in 23.1% of patients, compared to 14.7% in the standard care group. This represents a relative increase of 57% in diagnostic yield. The types of diagnoses made included various cardiac arrhythmias, such as atrial fibrillation and bradycardia, which are common culprits for syncope. The study also highlighted that the extended monitoring was particularly beneficial for patients with less frequent fainting episodes, as it increased the chances of capturing an event during the monitoring period. The trial's findings suggest that this take-home device approach could become a valuable tool in the diagnostic armamentarium for syncope, potentially reducing the need for more invasive or prolonged investigations and improving patient management.